KR920019779A - 치환된 인돌의 n-이미다졸릴 유도체 - Google Patents

치환된 인돌의 n-이미다졸릴 유도체 Download PDF

Info

Publication number
KR920019779A
KR920019779A KR1019920006840A KR920006840A KR920019779A KR 920019779 A KR920019779 A KR 920019779A KR 1019920006840 A KR1019920006840 A KR 1019920006840A KR 920006840 A KR920006840 A KR 920006840A KR 920019779 A KR920019779 A KR 920019779A
Authority
KR
South Korea
Prior art keywords
methyl
compound
formula
phenyl
indole
Prior art date
Application number
KR1019920006840A
Other languages
English (en)
Inventor
코찌 파올로
필란 안토니오
풀리치 마우리지오
살바티 파트리시아
다니엘 볼피 안젤로
Original Assignee
비토리노 페라디오
팜이탈리아 카를로 에르바 에스.알.엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비토리노 페라디오, 팜이탈리아 카를로 에르바 에스.알.엘 filed Critical 비토리노 페라디오
Publication of KR920019779A publication Critical patent/KR920019779A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

치환된 인돌의 N-이미다졸릴 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 일반식 (I)의 화합물 및 이의 약제학적으로 허용 가능한 염.
    상기식에서, p는 1내지 4의 정수이고, A는 직쇄 또는 측쇄의 C1-C4알킬렌 쇄이며, B는 직접 결합, 직쇄 또는 측쇄의 불포화 또는 포화된 C1-C4탄화수소 쇄이고, Q는 직쇄 또는 측쇄의 불포화 또는 포화된 C1-C9탄화수소쇄이고, 또는 이 쇄는 산소 원자에 의해 차단되며, R1및 R2는 각각 독립적으로 수소, C1-C4알킬, C1-C4알콕시,C1-C4알킬티오, C1-C4알킬설포닐, 할로겐 또는 트리할로메틸이고, R3및 R5는 각각 독립적으로 수소 또는 C1-C4알킬이며, R4는 -OR6또는 -N(R6R7)그룹 (여기에서, R6및 R7은 각각 독립적으로 수소, C1-C4알킬, 페닐 또는 벤질이다)이다.
  2. 제1항에 있어서, p는 1 또는 2이고, A가 -CH2-또는 -CH2-CH2-이며, B가 직접결합 또는 -CH2-이고, Q가 -CH2-CH2-, -CH2-CH2-CH2-, -CH2-C(CH3)2-, -CH2-CH2-C(CH3)2-, -CH2-O-CH2, -CH2-CH2-O-CH2-이며, R1및 R2가 각각 독립적으로 수소, C1-C4알킬, 할로겐 또는 트리플루오로메틸이고, R3가 C1-C4알킬이며, R5가 수소이고, R4가 -OR6또는 -NHR6(여기에서, R6는 수소 또는 C1-C4알킬이다)인 일반식(I)의 화합물 및 이의 약제학적으로 허용 가능한 염.
  3. 제1항에 있어서, p는 1 또는 2이고, A가 -CH2-이며, B가 직접결합 또는 -CH2-이고, Q가 -CH2-CH2-, -CH2-CH2-CH2-, -CH2-C(CH3)2-, -CH=CH- 또는 -CH2-O-CH2-이며, R2및 R5가 수소이고, R3가 C1-C4알킬이며, R1이 할로겐 또는 트리플루오로메틸이고, R4가 -OR6또는 -NHR6(여기에서, R6는 수소 또는 C1-C4알킬이다)인 일반식(I)의 화합물 및 이의 약제학적으로 허용 가능한 염.
  4. 5-플루오로-1-〔〔4-(1H-이미다졸-1-일)페닐〕메틸〕-3-메틸-1H-인돌-2-프로파노산; 5,7-디플루오로-1-〔〔4-(1H-이미다졸-1-일)페닐〕메틸〕-3-메틸-1H-인돌-2-프로파노산;5-플루오로-1-〔〔3-(1H-이미다졸-1-일)페닐〕메틸〕-3-메틸-1H-인돌-2-프로파노산;5-플루오로-1-〔〔4-(1H-이미다졸-1-일메틸)페닐〕메틸〕-3-메틸-1H-인돌-2-프로파노산;에틸 5-플루오로-1-〔〔4-(1H-이미다졸-1-일)페닐〕메틸〕-3-메틸-1H-인돌-2-프로파노에이트; 5-플루오로-1-〔〔4-(1H-이미다졸-1-일)페닐〕메틸〕-3-메틸-1H-인돌-2-프로파노아미드;5-플루오로-1-〔〔4-(1H-이미다졸-1-일)페닐〕메틸〕-α,α,3-트리메틸-1H-인돌-2-프로파노산; 5,7-디플루오로-1-〔〔4-(1H-이미다졸-1-일)페닐〕메틸〕-α,α,3-트리메틸-1H-인돌-2-프로파노산;5-플루오로-1-〔〔4-(1H-인다졸-1-일)페닐〕메틸〕-3-메틸-1H-인돌-2-부타노산;에틸5-플루오로-1-〔〔4-(1H-이미다졸-1-일)페닐〕메틸〕-3-메틸-1H-인돌-2-부타노에이트;5-플루오로-1-〔〔4-(1H-이미다졸-1-일)페닐〕메틸〕-α,α,3-트리메틸-1H-인돌-2-부타노산; 5,7-디플루오로-1-〔〔4-(1H-이미다졸-1-일)페닐〕메틸〕-α,α,3-트리메틸-1H-인돌-2-부타노산으로 이루어진 그룹중에서 선택되는 화합물 및 이의 약제학적으로 허용가능한 염.
  5. (a)일반식(Ⅱ)의 화합물 또는 이의 염을 일반식(Ⅲ)의 화합물과 반응시키거나, (b)일반식(Ⅳ)의 화합물을 일반식(Ⅴ)의 화합물과 반응물과 반응시키거나, (c)일반식(Ⅵ)의 화합물 또는 이이 염을 이미다졸, C1-C4알킬 이미다졸 또는 이의 염과 반응시키고, 필요한 경우, 일반식(I)의 화합물을 일반식(I)의 또다른 화합물로 전환시키고/시키거나, 필요한 경우 일반식(I)의 화합물을 이의 염으로 전환시키고/시키거나, 필요한 경우 일반식(I)의 화합물을 염을유리 화합물로 전환시키고/시키거나, 필요한 경우 일반식(I)의 화합물의 이성체의 혼합물을 단일한 이성체로 분리시킴을 특징으로 하여, 제1항에 따른 일반식(I)의 화합물, 또는 이의 약제학적으로 허용가능한 염을 제조하는 방법.
    상기식에서, p는 1내지 4의 정수이고, A는 직쇄 또는 측쇄의 C1-C4알킬렌 쇄이며, B는 직접 결합, 직쇄 또는 측쇄의 불포화 또는 포화된 C1-C4탄화수소 쇄이고, Q는 직쇄 또는 측쇄의 불포화 또는 포화된 C1-C9탄화수소쇄이고, 또는 이 쇄는 산소 원자에 의해 차단되며, R1및 R2는 각각 독립적으로 수소, C1-C4알킬, C1-C4알콕시,C1-C4알킬티오, C1-C4알킬설포닐, 할로겐 또는 트리할로메틸이고, R3및 R5는 각각 독립적으로 수소 또는 C1-C4알킬이며, R4는 -OR6또는 -N(R6R7)그룹(여기에서, R6및 R7은 각각 독립적으로 수소, C1-C4알킬, 페닐 또는 벤질이다)이고, Y는 이탈 그룹이다.
  6. 적합한 담체 및/또는 희석제 및 활성 성분으로서 제1항에 따른 일반식(I)의 화합물 또는 이의 약제학적으로 허용가능한 염을 포함하는 약제학적 조성물.
  7. 제1항에 있어서, TxA2합성이 증가되어 발병 효과를 나타내는 질환 상태를 치료하는데 사용하기 위한 일반식(I)의 화합물 또는 이의 약제학적으로 허용가능한 염.
  8. 제1항에 있어서, 심장 혈관 질환, 뇌 혈관 질환, 말초혈관 질환, 신장 질환, 호흡기 질환 또는 아테롬성 동맥경화증을 치료하는데 사용하기 위한 일반식(I)의 화합물 또는 이이 약제학적으로 허용가능한 염.
    ※ 참고사항 : 최초출원 내용에 공개하는 것임.
KR1019920006840A 1991-04-24 1992-04-23 치환된 인돌의 n-이미다졸릴 유도체 KR920019779A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9108811.2 1991-04-24
GB919108811A GB9108811D0 (en) 1991-04-24 1991-04-24 N-imidazolyl derivatives of substituted indole

Publications (1)

Publication Number Publication Date
KR920019779A true KR920019779A (ko) 1992-11-20

Family

ID=10693860

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920006840A KR920019779A (ko) 1991-04-24 1992-04-23 치환된 인돌의 n-이미다졸릴 유도체

Country Status (16)

Country Link
US (1) US5246957A (ko)
EP (1) EP0510398A3 (ko)
JP (1) JPH05132482A (ko)
KR (1) KR920019779A (ko)
AU (1) AU647907B2 (ko)
CA (1) CA2066938A1 (ko)
FI (1) FI921794A (ko)
GB (1) GB9108811D0 (ko)
HU (1) HUT60730A (ko)
IE (1) IE921314A1 (ko)
IL (1) IL101453A (ko)
MX (1) MX9201805A (ko)
MY (1) MY131096A (ko)
NZ (1) NZ242377A (ko)
RU (1) RU2073669C1 (ko)
TW (1) TW213911B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451597A (en) * 1993-05-27 1995-09-19 G.D. Searle & Co. Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists
EP0703913B1 (en) * 1993-06-14 1997-06-11 Pfizer Inc. Imidazoles as lipoxygenase inhibitors
JPH0867866A (ja) 1994-06-20 1996-03-12 Canon Inc 光重合剤及び／又は光架橋剤に対する可視光増感剤、感光性組成物及びホログラム記録媒体
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
DK1498124T3 (da) * 1997-10-17 2007-11-05 Ark Therapeutics Ltd Anvendelse af inhibitorer i renin-angiotensinsystemet
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
US20080275095A1 (en) * 2004-05-03 2008-11-06 Astellas Pharma Inc. Combination of Prostaglandin E2 Receptor Antagonists and Renin-Angiotensin System Inhibitors for Treating Renal Diseases
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
SG190667A1 (en) 2008-05-23 2013-06-28 Panmira Pharmaceuticals Llc 5-lipoxygenase-activating protein inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH455777A (de) * 1965-05-13 1968-05-15 Geigy Ag J R Verfahren zur Herstellung von neuen Indolderivaten
GR75101B (ko) * 1980-10-23 1984-07-13 Pfizer
ZA825413B (en) * 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
CA1241660A (en) * 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids
WO1987002664A1 (en) * 1985-10-30 1987-05-07 The Upjohn Company 3'-pyridinylalkylinden- and 3'-pyridinylalkylindol-2-carboxylic acids and analogs
US5081138A (en) * 1986-12-17 1992-01-14 Merck Frosst Canada, Inc. 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith
NZ222878A (en) * 1986-12-17 1991-02-26 Merck Frosst Canada Inc 3-hetero-substituted-n-benzyl-indole derivatives, and pharmaceutical compositions
GB8814277D0 (en) * 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
IL91542A0 (en) * 1988-10-06 1990-04-29 Erba Carlo Spa N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them
IT1227362B (it) * 1988-11-18 1991-04-08 Istituto Biochimico Italiano Derivati indolici, processo per la loro preparazione e loro uso comefarmaci antitrombotici
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung

Also Published As

Publication number Publication date
IL101453A (en) 1996-05-14
AU647907B2 (en) 1994-03-31
JPH05132482A (ja) 1993-05-28
IL101453A0 (en) 1992-12-30
HUT60730A (en) 1992-10-28
GB9108811D0 (en) 1991-06-12
EP0510398A3 (en) 1993-01-13
IE921314A1 (en) 1992-11-04
US5246957A (en) 1993-09-21
FI921794A0 (fi) 1992-04-22
TW213911B (ko) 1993-10-01
MX9201805A (es) 1994-07-29
NZ242377A (en) 1993-09-27
FI921794A (fi) 1992-10-25
AU1407992A (en) 1992-10-29
MY131096A (en) 2007-07-31
EP0510398A2 (en) 1992-10-28
RU2073669C1 (ru) 1997-02-20
CA2066938A1 (en) 1992-10-25
HU9201246D0 (en) 1992-07-28

Similar Documents

Publication Publication Date Title
KR920019779A (ko) 치환된 인돌의 n-이미다졸릴 유도체
KR950704294A (ko) 축합 벤조화합물(fused benzo compounds)
KR880007460A (ko) 3-헤테로-치환된-n-벤질-인돌
KR900003151A (ko) 화합물
IL81054A0 (en) Derivatives of((4)(4-(4-phenyl-1-piperazinyl)phenoxymethyl)-1,3-dioxolan-2-yl)methyl)-1h-imidazoles and 1h-1,2,4-triazoles,their preparation and their use for combating microorganisms
KR890001966A (ko) 함염성 아릴 유도체
HU907025D0 (en) Process for producing substituted n-(imidazolyl-alkyl)-alanine derivatives and pharmaceutical preparatives containing these compounds as active substance
IL106445A0 (en) 4-substituted 1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
JP2006504738A5 (ko)
HU9801950D0 (en) 2-(arylphenyl)-amino-imidazoline derivatives
KR940005558A (ko) 옥심 유도체
FI834702A (fi) Nya nitroalifatiska foereningar, deras framstaellningsfoerfarande och anvaendning.
EP0387070A3 (en) N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
KR20050099498A (ko) 사이클로옥시게나제 저해제로서 옥사졸 유도체
DE69612037D1 (de) Thiopyran Derivate
KR920014806A (ko) 치환된 테트라하이드로카바졸 및 사이클로헵트(b)인돌의 N-이미다졸릴 유도체
KR900012925A (ko) 인돌 유도체
DE69201184D1 (de) 5- Piperazinylalkyl-1,5-Benzothiazepinone verwendbar als Calciumantagonisten.
FR2726558A1 (fr) Nouvelles 5-(aryloxymethyl) oxazolines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR960031457A (ko) 점착성 수용체 길항제
KR910000652A (ko) (1,2,3,4-테트라하이드로-9-아크리딘이미노) 사이클로헥산 카복실산 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도
TNSN00015A1 (fr) Nouveaux sels de morpholinobenzamide
JPH02275846A (ja) カルボン酸誘導体
US5382592A (en) Antimigraine cyclobutenedione derivatives of tryptamines
NO180475C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid